Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.83 Consensus PT from Analysts

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has been given a consensus recommendation of “Buy” by the six ratings firms that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have covered the stock in the last year is $23.83.

Several brokerages recently issued reports on ACRV. Piper Sandler Companies reissued a “buy” rating and issued a $30.00 price target on shares of Acrivon Therapeutics in a report on Friday, September 6th. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Acrivon Therapeutics in a report on Monday, September 16th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $28.00 price objective (up previously from $25.00) on shares of Acrivon Therapeutics in a report on Monday, September 16th. JMP Securities restated a “market outperform” rating and issued a $17.00 target price on shares of Acrivon Therapeutics in a research report on Monday, September 16th. Finally, LADENBURG THALM/SH SH upgraded shares of Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Monday, September 16th.

Acrivon Therapeutics Price Performance

Acrivon Therapeutics stock opened at $8.25 on Friday. Acrivon Therapeutics has a 12 month low of $3.19 and a 12 month high of $11.90. The company has a fifty day moving average price of $7.97 and a two-hundred day moving average price of $7.89. The company has a market cap of $254.74 million, a PE ratio of -2.86 and a beta of 0.78.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.08. Equities research analysts anticipate that Acrivon Therapeutics will post -2.4 earnings per share for the current year.

Hedge Funds Weigh In On Acrivon Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. American International Group Inc. lifted its stake in shares of Acrivon Therapeutics by 39.2% in the 1st quarter. American International Group Inc. now owns 6,016 shares of the company’s stock worth $43,000 after acquiring an additional 1,695 shares during the period. Rhumbline Advisers lifted its position in Acrivon Therapeutics by 48.9% in the second quarter. Rhumbline Advisers now owns 16,209 shares of the company’s stock worth $94,000 after purchasing an additional 5,320 shares during the period. Dimensional Fund Advisors LP bought a new position in Acrivon Therapeutics during the 2nd quarter valued at $58,000. XTX Topco Ltd bought a new position in Acrivon Therapeutics during the 2nd quarter valued at $61,000. Finally, Bank of New York Mellon Corp increased its position in shares of Acrivon Therapeutics by 50.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 36,632 shares of the company’s stock valued at $212,000 after purchasing an additional 12,219 shares during the period. Institutional investors own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.